Multidisciplinary approach in the management of brain metastases from lung adenocarcinoma.
Brain metastases in lung adenocarcinoma are common and often present as complications in patients with advanced cancer. It worsen prognosis and reduce survival. Clinically, they vary from asymptomatic to intracranial hypertension syndrome. Multidi
Downloads
Bibliografía
American Cancer Society. (Jan de 2023). American Cancer Society. Obtenido de Key statistics for lung cancer: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
Gaspar L, S. C. (1997). Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys, 731 - 5. doi:10.1016/s0360-3016(96)00619-0
Gil del Otero J, R. C.-P. (2018). Management of cerebral edema in patients with brain tumors: A review. Rev Neurol, 305 - 314. doi:10.33588/rn.6609.2018005
Han Y, Y. H. (2017). Prognostic factors for survival in patients with brain metastases from non-small cell lung cancer treated with stereotactic radiosurgery: A retrospective analysis. Radiat Oncol, 12(1), 69. doi:10.1186/s13014-017-0815-5
Hasanov E, N. D. (2022). An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA CANCER J CLIN, 454 - 489.
Jhaveri J, M. A. (2012). Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). doi:10.1212/01.CON.0000411533.52691.13
Mathiesen TI, E. G. (2018). Surgery for brain metastases: a review of current literature and future directions. Cancer Treat Rev, 115 - 123.
Mathiesen TI, E. G. (2018). Surgery for brain metastases: a review of current literature and future directions. Cancer Treat Rev, 115 - 123. doi:10.1016/j.ctrv.2018.03.010
Ramalingam O, T. e. (2017). Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA. Lancet Oncol, 1454 - 1466. doi:10.1016/s1470-2045(17)30676-6
Reck M, R.-A. D. (2016). Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 1823 - 1833. doi:10.1056/NEJMoa1606774
Shin DY, N. I. (Mar de 2013). Characteristics of brain metastasis in patients with non-small cell lung cancer. Cancer Res Treat, 52 - 9. doi:10.4143/crt.2013.45.1.52
Soffietti R, A. U. (1 de Jul de 2017). Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 162 - 174. doi:10.1093/neuonc/nox073
Sperduto PW, B. B. (2008). A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys, 510 - 4. doi:10.1016/j.ijrobp.2007.06.074
Sun SQ, H. D. (2018). Surgical resection of brain metastases and the risk of leptomeningeal recurrence in patients treated with stereotactic radiosurgery. J Neurosurg, 161 - 168. doi:10.3171/2016.12.JNS161673
World Cancer Research Fund International. (Mar de 2022). World Cancer Research Fund International. Obtenido de Lung cancer statistics: https://www.wcrf.org/cancer-trends/lung-cancer-statistics/
Zeng Q, X. J. (2021). The efficacy and safety of antiepileptic drugs for patients with brain tumors: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol, 897 - 908. doi:10.1080/17512433.2021.1924357
Zhuang H, Y. Z. (2019). The prognostic value of primary tumor location in early-stage non-small cell lung cancer (NSCLC) patients after stereotactic body radiation therapy (SBRT). Radiat Oncol, 183. doi:10.1186/s13014-019-1385-5
Copyright (c) 2023 Hugo Castro
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 |
This work is licensed under Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
| Copyright notice |
 |
Authors will retain their copyright and assign to the journal the right of first publication of their work, which will be simultaneously subject to a Creative Commons Attribution-Noncommercial-ShareAlike 4.0 International license (CC BY-NC-SA 4.0) that allows third parties to share the work as long as its author and its first publication in this magazine are indicated. |
|
Authors may adopt other non-exclusive license agreements for the distribution of the version of the published work (eg: deposit it in an institutional repository or publish it in a monographic volume) provided that the initial publication in this journal is indicated. |
|
Authors are allowed and recommended to disseminate their work through the internet (eg, in institutional telematic files or on their website) before and during the submission process, which can lead to interesting exchanges and increase citations of the published work. (See The effect of open access). |
| About the Creative Commons license |
|
|
You are free to: |
|
Share — copy and redistribute the material in any medium or format. |
|
Adapt — remix, transform, and build upon the material. |
|
The licensor cannot revoke these freedoms as long as you follow the license terms. |
Under the following terms: |
 |
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. |
 |
NonCommercial — You may not use the material for commercial purposes. |
 |
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. |
| No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. |
